• Explore /
  • Poster
  • / Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan;

Kohei Shitara , Kei Muro , Jun Watanabe , Kentaro Yamazaki , Hisatsugu Ohori , Manabu Shiozawa , Hirofumi Yasui , Eiji Oki , Takeo Sato , Takeshi Naito , Yoshito Komatsu , Takeshi Kato , Junpei Soeda , Kouji Yamamoto , Riu Yamashita , Kiwamu Akagi , Atsushi Ochiai , Hiroyuki Uetake , Katsuya Tsuchihara , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT02394834

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 11)

DOI

10.1200/JCO.2023.41.4_suppl.11

Abstract #

11

Poster Bd #

A4

Abstract Disclosures

Similar Posters

First Author: Eiji Oki

First Author: Kei Muro

First Author: Yoshiaki Nakamura

First Author: Takayuki Yoshino